Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$JNJ Q1 '25 Earnings Results & Recap
Johnson & Johnson's Q1 2025 actual EPS of $2.77 was higher than the $2.58 estimate, while actual revenue of $21.9B exceeded the $21.56B estimate; however, the company still faced headwinds from biosimilar competition, particularly the 32.3% decline in Stelara sales, while key growth drivers like DARZALEX and Tremfya performed strongly, and the pipeline shows promise.7
